Pfizer Stock: A Rebound in the Making?

Pfizer (PFE) has been a standout performer in the healthcare sector in 2026, with its shares experiencing a significant increase of 18.58% year-to-date and 15.08% over the past month. The company’s stock has been trading at $28.07, which is essentially at the 52-week high of $28.44. This upward trend has caught the attention of Wall Street analysts, who are now predicting a rebound in the company’s stock price.

One of the key factors driving this rebound thesis is Pfizer’s robust pipeline of products, which includes 19 pivotal study starts planned across oncology, obesity, and immunology. The company’s CEO, Albert Bourla, has a proven track record of beating consensus revenue expectations, having done so in nine out of the past ten quarters. This level of execution and pipeline momentum has led analysts to assign a BUY rating to Pfizer stock with a price target of $32.36, representing a 15% upside from the recent close.

Why Bulls See a Breakout Ahead

The bull case for Pfizer stock rests on the company’s ability to execute on its pipeline products and deliver on its revenue guidance. The company’s launched and acquired products have grown operationally by 22% in Q1 2026, with Padcev and Nurtec ODT/Vydura experiencing significant growth of 39% and 42%, respectively. This level of growth is expected to continue, with Pfizer guiding for a high single-digit revenue CAGR from 2028 through 2033.

Furthermore, the company’s pipeline of products in oncology and obesity is expected to drive significant revenue growth in the coming years. If the obesity pipeline hits, analysts’ bull-case model reaches $36.17 within a year and $52.18 over five years. This level of growth would be a significant boost to the company’s stock price and would justify the BUY rating assigned by analysts.

Risks Worth Watching Now

While the bull case for Pfizer stock is strong, there are also risks worth watching. The company’s COVID-19 products, Comirnaty and Paxlovid, experienced significant declines in Q1 2026, falling 59% and 62%, respectively. Additionally, generic and biosimilar competition is expected to drag roughly $1.5 billion off 2026 revenue, and the company has no plans to undertake share buybacks despite having a $3.3 billion authorization.

These risks would need to be carefully managed by the company in order to achieve the level of growth predicted by analysts. However, if the company is able to execute on its pipeline products and deliver on its revenue guidance, the upside potential for the stock is significant.

How Pfizer Compares to Merck and Bristol Myers Squibb

Pfizer’s valuation multiple of 10x forward earnings is significantly lower than that of its peers, Merck and Bristol Myers Squibb, which trade at 18x and 11x forward earnings, respectively. This valuation gap is the primary reason why Pfizer stock looks like a rebound trade, according to analysts.

Merck’s KEYTRUDA, a leading oncology product, posted $8.03 billion in Q1 2026 sales, up 12%. While this is a significant achievement, it is not enough to justify the higher valuation multiple assigned to Merck. Bristol Myers Squibb’s shares also trade at a premium to Pfizer, with a valuation multiple of 11x forward earnings. However, the company’s co-marketing agreement with Pfizer for Eliquis provides a level of synergy that is not present in the Pfizer-Merck comparison.

Pfizer Price Prediction 2026-2030

Analysts’ 24/7 Wall St. price target for Pfizer stock is $32.36, representing a 15% upside from the recent close. This price target is based on a combination of factors, including the company’s robust pipeline of products, its track record of beating consensus revenue expectations, and its attractive valuation multiple relative to its peers.

The bullish setup for Pfizer stock strengthens if oncology and obesity readouts continue to land and COVID declines stabilize near management’s $4 billion guide. However, if Paxlovid disappoints again or the Metsera obesity data underwhelm in 2027, the thesis would weaken.